£88m Series B For Syncona-backed Freeline To Advance Liver Gene Therapy Focus
Chairman says Freeline's series B financing gives it adequate funds for Phase I/II trials in hemophilia B and entry into Fabry disease.
Chairman says Freeline's series B financing gives it adequate funds for Phase I/II trials in hemophilia B and entry into Fabry disease.